Clinical outcomes by race in a phase 1-2 trial of neoadjuvant durvalumab plus chemotherapy for early-stage TNBC

The incidence of triple-negative breast cancer (TNBC) is higher among African American (AA) women compared with European American (EA) women; yet AA women are underrepresented in clinical trials. To evaluate the safety and efficacy of neoadjuvant durvalumab plus chemotherapy for stage I-III TNBC by race, a phase 1-2 study at Yale University (New Haven, CT) enrolled additional AA patients. The study found that pCR rates, 3-year EFS and 3-year OS after neoadjuvant chemoimmunotherapy were similar in AA and non-AA patients. Toxicities, including the frequency of irAEs, were also similar.